16 results
8-K
EX-10.2
SYRS
Syros Pharmaceuticals Inc.
13 Oct 21
Departure of Directors or Certain Officers
4:01pm
and the Company, the right to exercise this option shall terminate immediately upon such violation.
(d) Exercise Period Upon Death or Disability … the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized
8-K
EX-2.1
SYRS
Syros Pharmaceuticals Inc.
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
or long-term disability benefit plan
(h) No Tyme Employee Plan is subject to any law of a foreign jurisdiction outside of the United States.
(i) No Tyme … of any Subsidiary under any workers’ compensation policy or long-term disability policy. Neither Tyme nor any of its Subsidiaries is a party
S-4
EX-10.5
cnh500h3k9 3btwaq
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
8-K
EX-99.1
zad9pmk
15 Sep 22
Departure of Directors or Certain Officers
4:06pm
425
l0bq7
15 Sep 22
Business combination disclosure
4:08pm
PRE 14A
doffife67y68sjapoe4p
12 Apr 24
Preliminary proxy
4:30pm
425
8j36xky2i4fcxjh97
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-2.1
h73ffmqufp5
7 Dec 20
Entry into a Material Definitive Agreement
6:05am
8-K
EX-1.1
787sha sg3
13 Feb 20
Syros Announces $60 Million Loan Facility with Oxford Finance LLC
8:51am
- Prev
- 1
- Next